Communication Pharmaceutical Companies Pharmaceutical Manufacturing 
Pharmaceutical Commerce
JUNE 17, 2025
Structuring patient assistance programs as independent non-profit foundations helps pharmaceutical companies reduce regulatory and legal exposure while allowing for more holistic, patient-centered support. Lastly, PAPs that are directly managed by pharmaceutical companies may also struggle with public image issues.
Pharma Marketing Network
JULY 9, 2025
Manufacturing Dependencies and Global Disruption Pharmaceutical manufacturing doesn’t operate within national borders. Impact on Pharma Marketing and Innovation Budgets If 200% tariffs become the norm, pharmaceutical companies will face brutal budget reallocations. One of the first budgets to feel the pinch?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JUNE 19, 2025
Large pharmaceutical companies such as AbbVie, Lilly, Roche and Takeda have demonstrated strong interest in licensing innovator oligonucleotides for CNS indications, accounting for 63% of licensing deals between 2021 and 2025 year-to-date. ASOs accounted for more than half ($3.54 billion), while siRNAs made up more than a third ($2.51
European Pharmaceutical Review
JULY 9, 2025
What is the role of a CDMO during the fill and finish stage in pharmaceutical manufacturing? It represents one of the highest-risk stages in sterile pharmaceutical manufacturing” The importance of fill and finish cannot be overstated. Why is it important?
Pharmaceutical Technology
JUNE 30, 2025
These ongoing legal challenges highlight the volatility of today’s macroeconomic environment – just one aspect of the complex and volatile world that pharmaceutical manufacturers now find themselves in. Mitigating the challenges Companies are taking actions to minimise the impact on their businesses.
Pharmaceutical Technology
JUNE 11, 2025
Robert Barrie June 11, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Drugmakers have poured billions of dollars into pharma manufacturing facilities across the US as they adapt to macroeconomic pressures. Conversely, foreign manufacturing plants will be subject to increased inspection fees.
Viseven
MAY 9, 2025
Source: [link] Demonstrating value Pharmaceutical companies are expected to go beyond simply proving that their treatments work they need to show that their products provide real, measurable benefits for both patients and healthcare systems. How Does the HEOR Model Work for Pharmaceutical Companies?
Expert insights. Personalized for you.
59 
Let's personalize your content